Pricing Log in Create free account
Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue
+3,749.2%
EPS
+549.1%
Free cash flow
+839.7%

Quarter to June 2026, against a year earlier

132.51 2.75 −2.03%
Market cap
$8.8B
P/E
111×
Fwd P/E
31.2×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Protagonist Therapeutics, Inc. (PTGX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 18 added · 15 removed · 34 modified
P2I1A: no material changes, the filing says
8-K Nov 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 21 added · 5 removed · 33 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jun 17, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 82 added · 101 removed · 68 modified
1A: 19 added · 3 removed · 66 modified
7: 22 added · 68 removed · 35 modified
8-K Feb 25, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 Receivables outpacing revenue
8-K Feb 21, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 27, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.